Indication: B-Cell Non-Hodgkin Lymphoma (NHL)

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (017006)

Failed front-line therapy/not eligible for HSCT

Sub-indication: DLBCL

Line of Therapy: second line

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Juno Therapeutics, Inc

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.